BSX's Endoscopy unit targets an $8B market, spanning pancreaticobiliary, surgery and obesity, with plans to outgrow the market.
Both companies are high-quality MedTech leaders, but their upside profiles diverge. Stryker’s diversification, consistent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback